(Q37803409)

23 August 2017

title

Tocilizumab for the treatment of rheumatoid arthritis. (English)

1 reference

23 August 2017

1 reference

1 reference

Toshio Tanaka

1

1 reference

23 August 2017

Atsushi Ogata

series ordinal

2

1 reference

23 August 2017

Masashi Narazaki

series ordinal

3

1 reference

23 August 2017

publication date

1 November 2010

1 reference

Expert Review of Clinical Immunology

23 August 2017

published in

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

843-854

1 reference

Interleukin-6: from basic science to medicine--40 years in immunology

23 August 2017

cites work

1 reference

Impaired immune and acute-phase responses in interleukin-6-deficient mice.

21 January 2018

1 reference

IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase

21 January 2018

1 reference

Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130

21 January 2018

1 reference

Structure and function of a new STAT-induced STAT inhibitor

21 January 2018

1 reference

Cytokine signal transduction

21 January 2018

1 reference

Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production

21 January 2018

1 reference

New therapies for treatment of rheumatoid arthritis

21 January 2018

1 reference

Interleukin 6 plays a key role in the development of antigen-induced arthritis

21 January 2018

1 reference

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

21 January 2018

1 reference

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

21 January 2018

1 reference

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

21 January 2018

1 reference

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

21 January 2018

1 reference

Recommendations of the German rheumatology society on the use of tocilizumab in rheumatoid arthritis

21 January 2018

1 reference

Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?

21 January 2018

1 reference

Anti-interleukin 6: first line in rheumatoid arthritis?

21 January 2018

1 reference

21 January 2018

1 reference

Mycobacterial disease in patients with rheumatic disease

21 January 2018

1 reference

IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system

21 January 2018

1 reference

Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression.

21 January 2018

1 reference

Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis

21 January 2018

1 reference

Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis

21 January 2018

1 reference

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody

21 January 2018

1 reference

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 January 2018

1 reference

Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECI.10.70

1 reference

23 August 2017

1 reference